Drug Development RFP
Funds early-stage clinical trials and IND-enabling studies for novel drugs and devices targeting Alzheimer’s disease, excluding anti-amyloid and cholinesterase inhibitor approaches.
Funder: Alzheimer's Drug Discovery Foundation
Due Dates: September 14, 2026: Letter of Intent deadline (must be received by 5:00 pm ET)
Funding Amounts: Up to $5,000,000 per project; multi-year funding; milestone-based payments.
Summary: Supports IND-enabling studies and early-phase clinical trials for novel drugs and devices targeting Alzheimer’s disease and related dementias.
Key Information: Anti-amyloid and cholinesterase inhibitor proposals are not eligible.
Description
This opportunity funds investigational new drug (IND)-enabling studies and early-phase clinical trials for pharmacological interventions and devices targeting Alzheimer’s disease and related dementias. The focus is on diverse drug mechanisms related to the biology of aging and emerging therapeutic areas, such as epigenetics, inflammation, mitochondrial function, neuroprotection, proteostasis, synaptic activity, and vascular function. Both novel and repurposed drugs, natural products, and devices are eligible, provided there is strong biological rationale and preliminary data. Anti-amyloid and cholinesterase inhibitor projects are specifically excluded. Combination therapies and projects with innovative intellectual property strategies are encouraged. Proposals should include biomarker-based outcomes and involve multidisciplinary teams.
